Bay Colony Advisory Group, Inc d/b/a Bay Colony Advisors - CRISPR THERAPEUTICS AG ownership

CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 420 filers reported holding CRISPR THERAPEUTICS AG in Q2 2023. The put-call ratio across all filers is 0.90 and the average weighting 0.2%.

Quarter-by-quarter ownership
Bay Colony Advisory Group, Inc d/b/a Bay Colony Advisors ownership history of CRISPR THERAPEUTICS AG
ValueSharesWeighting
Q3 2023$312,397
-20.6%
6,883
-1.8%
0.08%
-21.1%
Q2 2023$393,401
+26.0%
7,008
-0.9%
0.10%
+15.9%
Q1 2023$312,211
+7.1%
7,070
-1.4%
0.08%
+6.5%
Q4 2022$291,461
-39.5%
7,170
-2.7%
0.08%
-46.2%
Q3 2022$482,000
-12.8%
7,3700.0%0.14%
+1.4%
Q2 2022$553,000
+52.8%
7,370
+27.7%
0.14%
+62.1%
Q1 2022$362,000
-9.5%
5,770
+9.4%
0.09%
-23.7%
Q4 2021$400,000
-9.9%
5,272
+32.8%
0.11%
-21.4%
Q3 2021$444,000
-31.4%
3,971
-0.7%
0.14%
-32.9%
Q2 2021$647,000
+32.9%
3,9990.0%0.22%
+16.1%
Q1 2021$487,000
+23.9%
3,999
+55.6%
0.19%
-11.0%
Q4 2020$393,000
+24.0%
2,570
-32.3%
0.21%
+6.1%
Q3 2020$317,000
+41.5%
3,795
+24.4%
0.20%
+21.6%
Q2 2020$224,000
-3.0%
3,050
-22.8%
0.16%
+8.0%
Q4 2019$231,000
+13.8%
3,950
-20.2%
0.15%
+8.7%
Q3 2019$203,000
-12.9%
4,9500.0%0.14%
-8.0%
Q2 2019$233,000
+13.1%
4,950
-16.1%
0.15%
+10.3%
Q1 2019$206,0005,9000.14%
Other shareholders
CRISPR THERAPEUTICS AG shareholders Q2 2023
NameSharesValueWeighting ↓
Versant Venture Management, LLC 508,558$82,330,00027.28%
Valiant Capital Management, L.P. 307,700$49,814,0003.74%
NEA Management Company, LLC 1,590,002$257,405,0003.35%
NIA IMPACT ADVISORS, LLC 39,891$6,458,0003.15%
Ikarian Capital, LLC 200,000$32,379,0002.62%
Soleus Capital Management, L.P. 103,114$16,693,0002.57%
HIMENSION CAPITAL (SINGAPORE) PTE. LTD. 157,334$25,471,0002.47%
Capital Impact Advisors, LLC 45,440$7,356,0002.37%
ARK Investment Management 7,776,119$1,258,876,0002.34%
Sassicaia Capital Advisers LLC 13,513$2,188,0002.28%
View complete list of CRISPR THERAPEUTICS AG shareholders